Next Article in Journal
Does the Modification of Serine 477 of DNA Mismatch Repair Protein MLH1 Play a Role in Cell Proliferation?
Previous Article in Journal
The Cytotoxic Effect of 64Cu/NOTA-Terpyridine Platinum Conjugate, as a Novel Chemoradiotherapy Agent
 
 
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Abstract

The Pluripotency Transcription Factor Oct4 Contributes to Head and Neck Squamous Cell Carcinoma Radioresistance via Regulation of DNA Repair and the Stem Cell Phenotype †

1
OncoRay-National Center for Radiation Research in Oncology, Faculty of Medicine and University Hospital Carl Gustav Carus, Technische Universität Dresden, Helmholtz-Zentrum Dresden-Rossendorf, 01307 Dresden, Germany
2
Helmholtz-Zentrum Dresden-Rossendorf, Institute of Radiooncology-OncoRay, 01307 Dresden, Germany
3
Laboratory of Radiobiology and Experimental Radiooncology, Center of Oncology, University Medical Center Hamburg-Eppendorf, 20251 Hamburg, Germany
4
German Cancer Consortium (DKTK), Partner Site Dresden and German Cancer Research Center (DKFZ), 69120 Heidelberg, Germany
5
Department of Radiotherapy and Radiation Oncology, Faculty of Medicine and University Hospital Carl Gustav Carus, Technische Universität Dresden, 01307 Dresden, Germany
6
German Cancer Research Center (DKFZ), 69120 Heidelberg, Germany
7
National Center for Tumor Diseases (NCT), 69120 Heidelberg, Germany
*
Author to whom correspondence should be addressed.
Presented at the 1st International Electronic Conference on Cancers: Exploiting Cancer Vulnerability by Targeting the DNA Damage Response, 1–14 February 2021; Available online: https://iecc2021.sciforum.net/.
Med. Sci. Forum 2021, 3(1), 5; https://doi.org/10.3390/IECC2021-09224
Published: 31 January 2021

Abstract

:
Despite being the sixth most common cancer type worldwide, head and neck squamous cell carcinoma (HNSCC) exhibits low five-year survival rates for advanced-stage patients. The local control probability after radiotherapy crucially depends on efficient depletion of the pluripotent sub-population of tumor cells. These cancer stem cells (CSCs) are characterized by an active DNA repair and, consequently, an enhanced radio(chemo)therapy resistance. This study provides evidence that due to its involvement in the regulation of the DNA damage response and stem cell phenotype, the CSC-related transcription factor Oct4 contributes to HNSCC radioresistance. In a siRNA-mediated Oct4 knockdown model, we observed reduced self-renewal capacity and partial radiosensitization of HNSCC cell lines accompanied by decreased expression of the cell cycle checkpoint kinases Chk-1 and WEE1. Consequently, Oct4 knockdown impaired the G2 checkpoint induction after irradiation, linking Oct4 to the HNSCC DNA damage response. Upon CRISPR/Cas9-mediated knockout of the pluripotency-related isoform Oct4 A, radiosensitization of HNSCC cells could only be achieved in combination treatment with the PARP inhibitor Olaparib. In addition, irradiation-induced up-regulation of DNA repair genes, such as the homologous recombination repair (HRR) gene BRCA1, was abolished in Oct4 A knockout cells, indicating that Oct4 A depletion leads to HRR deficiency in HNSCC cells. Further analysis of the Oct4-correlating gene signature in the HNSCC TCGA patient dataset identified the HRR genes PSMC3IP and RAD54L showing a significant correlation with the overall survival of radiotherapy-treated HNSCC patients. The HNSCC self-renewal capacity and clonogenic cell survival after irradiation was reduced upon siRNA-mediated PSMC3IP and RAD54L knockdown, emphasizing the interplay between DNA repair and the CSC phenotype in HNSCC radioresistance mechanisms. All in all, the involvement of Oct4 in the regulation of DNA repair and cell cycle progression provides new insights into HNSCC radioresistance and opens possibilities for combination therapy with PARP inhibitors.

Supplementary Materials

The following are available online at https://www.mdpi.com/article/10.3390/IECC2021-09224/s1.

Institutional Review Board Statement

Ethical approval for this retrospective analysis of clinical and biological data was obtained from the local Ethics Committee.

Informed Consent Statement

Written informed consent was obtained from all patients.

Data Availability Statement

All data supporting the findings of this study are available from the corresponding authors upon request. Gene expression data generated during the study available in the public repository Gene Expression Omnibus (GEO), accession no GSE173161.
Publisher’s Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Share and Cite

MDPI and ACS Style

Nathansen, J.; Lukiyanchuk, V.; Hein, L.; Stolte, M.-I.; Borgmann, K.; Löck, S.; Kurth, I.; Krause, M.; Linge, A.; Dubrovska, A. The Pluripotency Transcription Factor Oct4 Contributes to Head and Neck Squamous Cell Carcinoma Radioresistance via Regulation of DNA Repair and the Stem Cell Phenotype. Med. Sci. Forum 2021, 3, 5. https://doi.org/10.3390/IECC2021-09224

AMA Style

Nathansen J, Lukiyanchuk V, Hein L, Stolte M-I, Borgmann K, Löck S, Kurth I, Krause M, Linge A, Dubrovska A. The Pluripotency Transcription Factor Oct4 Contributes to Head and Neck Squamous Cell Carcinoma Radioresistance via Regulation of DNA Repair and the Stem Cell Phenotype. Medical Sciences Forum. 2021; 3(1):5. https://doi.org/10.3390/IECC2021-09224

Chicago/Turabian Style

Nathansen, Jacqueline, Vasyl Lukiyanchuk, Linda Hein, Maya-Isabel Stolte, Kerstin Borgmann, Steffen Löck, Ina Kurth, Mechthild Krause, Annett Linge, and Anna Dubrovska. 2021. "The Pluripotency Transcription Factor Oct4 Contributes to Head and Neck Squamous Cell Carcinoma Radioresistance via Regulation of DNA Repair and the Stem Cell Phenotype" Medical Sciences Forum 3, no. 1: 5. https://doi.org/10.3390/IECC2021-09224

Article Metrics

Back to TopTop